Related Experiment Video
Updated: Dec 22, 2025
06:28
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
7.1K
Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk
Rhodri J King1, Katharina Schuett2, Christian Tiede3
1Leeds Institute for Cardiovascular and Metabolic Medicine, Leeds, UK.
Haematologica
|May 2, 2020
Summary
Complement C3 binding to fibrinogen increases thrombosis risk by inhibiting clot lysis. Disrupting this interaction with Affimer proteins enhances fibrinolysis, offering a new therapeutic target for high-risk individuals.
Area of Science:
- Biochemistry
- Hematology
- Immunology
Background:
- Complement C3 (C3) interacts with fibrinogen, impairing fibrin clot lysis and elevating thrombosis risk.
- Understanding the C3-fibrinogen interaction is crucial for developing novel antithrombotic strategies.
Purpose of the Study:
- To investigate the C3-fibrinogen interaction as a therapeutic target for reducing thrombosis.
- To analyze C3's fibrinolytic properties, identify interaction sites, and modulate lysis by disrupting the interaction.
Main Methods:
- Assessed inter-individual variability in C3's anti-fibrinolytic effects using purified fibrinogen and C3.
- Employed microarray screening and molecular modeling to pinpoint C3-fibrinogen binding sites.
- Utilized synthetic Affimer proteins to modulate the C3-fibrinogen interaction and fibrinolysis.
Main Results:
- C3 from type 1 diabetes patients significantly prolonged fibrinolysis compared to healthy controls.
- Identified two potential C3-fibrinogen interaction sites on the fibrinogen β-chain.
- An Affimer targeting the C3-fibrinogen interaction abolished C3-induced lysis prolongation and enhanced overall fibrinolysis.
Conclusions:
- C3 binds to the fibrinogen β-chain, contributing to thrombosis risk.
- Disruption of the C3-fibrinogen interaction via Affimer proteins enhances fibrinolysis.
- This interaction represents a promising novel therapeutic target for reducing thrombosis in high-risk populations.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
01:27Complement System
8.8K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
8.8K
01:16Clot Retraction and Fibrinolysis
8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
01:29Venous Thrombosis III: Interprofessional Care
211
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
211
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.4K